These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 8732472)

  • 1. Efficacy and safety of Menorest in two positive-controlled studies.
    Pornel B
    Eur J Obstet Gynecol Reprod Biol; 1996 Apr; 64 Suppl():S35-7. PubMed ID: 8732472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of Menorest 50 compared with Estraderm TTS 50 in the treatment of postmenopausal symptoms. A randomized, multicenter, parallel group study.
    Pornel B; Genazzani AR; Costes D; Dain MP; Lelann L; Vandepol C
    Maturitas; 1995 Nov; 22(3):207-18. PubMed ID: 8746878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of Menorest (50 mikrog/day) compared to Premarin 0.625 mg in the treatment of menopausal symptoms and the prevention of bone loss, in menopausal women. A single-center, comparative, randomized, double-blind, double-dummy study.
    Studd JW; MacCarthy K; Zamblera D; Dain MP
    Scand J Rheumatol Suppl; 1996; 103():89-90. PubMed ID: 8966497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Menorest: a clinical overview.
    Wren B
    Int J Gynaecol Obstet; 1996 Mar; 52 Suppl 1():S27-9. PubMed ID: 8666124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerance of Menorest compared to Premarin in the treatment of postmenopausal women. A randomised, multicentre, double-blind, double-dummy study.
    Studd JW; McCarthy K; Zamblera D; Burger HG; Silberberg S; Wren B; Dain MP; Le Lann L; Vandepol C
    Maturitas; 1995 Sep; 22(2):105-14. PubMed ID: 8538478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double-blind comparative study of Estraderm and Premarin in the amelioration of postmenopausal symptoms.
    Place VA; Powers M; Darley PE; Schenkel L; Good WR
    Am J Obstet Gynecol; 1985 Aug; 152(8):1092-9. PubMed ID: 2992278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the local tolerability and adhesion of a new matrix system (Menorest) for estradiol delivery with an established transdermal membrane system (Estraderm TTS).
    Erianne JA; Winter L
    Maturitas; 1997 Mar; 26(2):95-101. PubMed ID: 9089558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HRT and long-term compliance: the efficacy and safety of Menorest.
    Studd J; Panay N; Zamblera D; Leather AT
    Int J Gynaecol Obstet; 1996 Mar; 52 Suppl 1():S21-5. PubMed ID: 8666123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy on climacteric symptoms of a new estradiol transdermal patch with active matrix in comparison with a reference reservoir patch. Two long-term randomized multicenter parallel-group studies.
    Rovati LC; Schmid K; Giacovelli G; Bonn M; Setnikar I; Wolff F; Genazzani AR
    Arzneimittelforschung; 1999 Nov; 49(11):933-43. PubMed ID: 10604047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteoporosis prevention clinical study program.
    Delmas P; Gimona A
    Eur J Obstet Gynecol Reprod Biol; 1996 Apr; 64 Suppl():S39-45. PubMed ID: 8732473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical experience with a seven-day estradiol transdermal system for estrogen replacement therapy.
    Gordon SF
    Am J Obstet Gynecol; 1995 Sep; 173(3 Pt 2):998-1004. PubMed ID: 7573298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of climacteric syndrome using Estraderm TTS and premarin in a comparative study].
    Leodolter S; Sainz H; Moll-Schüler I; Mach R
    Gynakol Geburtshilfliche Rundsch; 1992; 32(4):201-4. PubMed ID: 1337708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 17Beta-estradiol delivered by three different matrix patches 50 microg/day: a three way cross-over study in 21 postmenopausal women.
    Rohr UD; Nauert C; Stehle B
    Maturitas; 1999 Sep; 33(1):45-58. PubMed ID: 10585173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of two estradiol transdermal systems (Oesclim 50 and Estraderm TTS 50). I. Tolerability, adhesion and efficacy.
    Rozenbaum H; Birkhäuser M; De Nooyer C; Lambotte R; Pornel B; Schneider H; Studd J
    Maturitas; 1996 Nov; 25(3):161-73. PubMed ID: 8981333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy on climacteric symptoms and safety of low dose estradiol transdermal matrix patches. A randomized, double-blind placebo-controlled study.
    De Aloysio D; Rovati LC; Giacovelli G; Setnikar I; Bottiglioni F
    Arzneimittelforschung; 2000 Mar; 50(3):293-300. PubMed ID: 10758784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of Estraderm MX, a new estradiol matrix patch.
    Bacchi-Modena A; Bolis P; Campagnoli C; De Cicco F; Meschia M; Pansini F; Pisati R; Hüls G
    Maturitas; 1997 Jul; 27(3):285-92. PubMed ID: 9288701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of a seven-day, transdermal estradiol drug-delivery system: comparison with conjugated estrogens and placebo. The Transdermal Estradiol Patch Study Group.
    Gordon SF; Thompson KA; Ruoff GE; Imig JR; Lane PJ; Schwenker CE
    Int J Fertil Menopausal Stud; 1995; 40(3):126-34. PubMed ID: 7663539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical study comparing the effects of sequential hormone replacement therapy with oestradiol/dydrogesterone and conjugated equine oestrogen/norgestrel on lipids and symptoms.
    Cieraad D; Conradt C; Jesinger D; Bakowski M
    Arch Gynecol Obstet; 2006 May; 274(2):74-80. PubMed ID: 16491367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomised study to compare the efficacy and safety of new 17 beta-oestradiol transdermal matrix patch with Estraderm TTS 50 in hysterectomised postmenopausal women. The Lyrelle Study Group.
    al-Azzawi F; Van der Mooren MJ; Rolland R; Hirvonen E
    Br J Clin Pract; 1997; 51(1):20-3, 25-6. PubMed ID: 9158267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of two estradiol transdermal systems (Oesclim 50 and Estraderm TTS 50). II. Local skin tolerability.
    Rozenbaum H; Birkhäuser M; De Nooyer C; Lambotte R; Pornel B; Schneider H; Studd J; Thebault J
    Maturitas; 1996 Nov; 25(3):175-85. PubMed ID: 8981334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.